SCHEMBL5544136

SCHEMBL5544136

CC(C)(C)OC(=O)N1CCC(N2C(=O)[N]c3cc(Cl)ccc32)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 5/20 0.48
CTSD P07339 1/20 0.46
CTSE P14091 1/20 0.46
BACE1 P56817 1/20 0.46
NR3C1 P04150 2/20 0.46
CNR1 P21554 2/20 0.45
CNR2 P34972 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.44
MDM2 Q00987 1/20 0.44
TNF P01375 1/20 0.44
LITAF Q99732 1/20 0.44
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540935 0.88 SMN1; SMN2 (0.49) CTSDCTSEBACE1MEN1KMT2A
SCHEMBL5535999 0.85 GPR119 (0.49) STSCTSDCTSEBACE1MEN1
SCHEMBL4715434 0.80 NOTUM (0.47) STSCTSDCTSEBACE1CNR1
SCHEMBL4717139 0.80 NOTUM (0.52) STSCNR1CNR2
SCHEMBL4713768 0.79 MEN1 (0.45) STSCTSDCTSEBACE1CNR1
SCHEMBL5542712 0.79 NOTUM (0.42) MDM2
SCHEMBL3411142 0.78 OXTR (0.46)
SCHEMBL27219001 0.76 NOTUM (0.48) STSCNR1CNR2MEN1KMT2A
SCHEMBL26915965 0.76 NOTUM (0.48) STSCNR1CNR2MEN1KMT2A
SCHEMBL4716565 0.76 UTS2R (0.49) STSCTSDCTSEBACE1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 STS 2306/4885CTSD 4687/4885CTSE 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.